Results 11 to 20 of about 13,123 (252)

Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery [PDF]

World Journal of Surgical Oncology
Background Small bowel obstruction (SBO) affects ~ 30% of ovarian cancer (OC) patients, leading to readmission, debilitating symptoms, and death within one year. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) effectively
Luis Felipe Falla-Zuniga, Armando Sardi, Mary Caitlin King, Felipe Lopez-Ramirez, Vladislav Kovalik, Sergei Iugai, Teresa Diaz-Montes, Vadim Gushchin   +7 more
doaj   +2 more sources

Factors influencing hematological toxicity and adverse effects of perioperative hyperthermic intraperitoneal vs intraperitoneal chemotherapy in gastrointestinal cancer [PDF]

Open Medicine
Intraperitoneal (IP) chemotherapy (IPC), including hyperthermic intraperitoneal chemotherapy (HIPEC), has emerged as a promising approach to control peritoneal metastases in gastrointestinal (GI) cancers. However, the safety profile and toxicity spectrum
Zhang Xue, Zheng Zhewen, Gao Hui, Yang Ziqi, Bai Jian   +4 more
doaj   +2 more sources

Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer [PDF]

Obstetrics & Gynecology Science, 2021
Objective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer.
Jieun Ko, Hyeong In Ha, Min Chul Choi, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Joon Mo Lee   +8 more
doaj   +1 more source

Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis

International Journal of Hyperthermia, 2023
Background The original meta-analysis of hyperthermic intraperitoneal chemotherapy (HIPEC) is already outdated, owing to the latest trial results. This study aimed to clarify the efficacy and adverse events of cytoreductive surgery with HIPEC compared to
Yu Xia, He Wang, Jing Zhang, Yongjun Wang   +3 more
doaj   +1 more source

Peritoneal Cancer Index Dominates Prognosis After CRS-HIPEC for Colorectal Peritoneal Metastases: A Consecutive Single-Centre Cohort with 3-Year Follow-Up. [PDF]

Cancers (Basel)
Kazanowski M, Lesiak P, Wierzbicki J, Kapturkiewicz B, Maciejewski P, Pawłowski M, Jastrzębski T, Bębenek M.   +7 more
europepmc   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): New Approaches and Controversies on the Treatment of Advanced Epithelial Ovarian Cancer—Systematic Review and Meta-Analysis

Journal of Clinical Medicine, 2023
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has been extensively studied in patients with peritoneal carcinomatosis, and it holds promise as a therapeutic strategy, but its role remains elusive.
L. Della Corte, Carmine Conte, M. Palumbo, Serena Guerra, Dario Colacurci, G. Riemma, Pasquale De Franciscis, P. Giampaolino, A. Fagotti, Giuseppe Bifulco, G. Scambia   +10 more
semanticscholar   +1 more source

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer

Annals of Surgical Oncology, 2023
Background Selected patients with peritoneal metastases of colorectal cancer (PM-CRC) can benefit from potentially curative cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC), with a median overall survival (OS) of more than ...
Martin Hübner, K. van der Speeten, K. Govaerts, I. D. de Hingh, L. Villeneuve, S. Kusamura, O. Glehen   +6 more
semanticscholar   +1 more source

Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence

Cancers, 2023
Simple Summary Iterative cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases remain controversial regarding safety and efficacy.
E. Pasqual, A. Londero, M. Robella, M. Tonello, A. Sommariva, M. De Simone, S. Bacchetti, G. Baiocchi, S. Asero, F. Coccolini, F. De Cian, M. Guaglio, A. Cinquegrana, Carola Cenzi, S. Scaringi, A. Macrì   +15 more
semanticscholar   +1 more source

Enhanced Recovery after Surgery (ERAS) Program for Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery with or without HIPEC: A Systematic Review and a Meta-Analysis

Cancers, 2023
Simple Summary Cytoreductive surgery and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) represent a promising treatment strategy for the management of selected cases of peritoneal cancer, but it’s still burdened by significant morbidity and prolonged ...
M. Robella, M. Tonello, P. Berchialla, V. Sciannameo, Alba Ilari Civit, A. Sommariva, C. Sassaroli, A. di Giorgio, R. Gelmini, V. Ghirardi, F. Roviello, F. Carboni, P. Lippolis, S. Kusamura, M. Vaira   +14 more
semanticscholar   +1 more source

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Journal of Clinical Medicine, 2023
Simple Summary Advanced gastric cancer (GCa) is associated with poor prognosis due to the challenge of peritoneal disease, the most common site of metastasis at initial diagnosis, staging laparoscopy, and recurrence.
Anish J Jain, B. Badgwell
semanticscholar   +1 more source